Daily Archive: November 28, 2011

Nov 28

Audio highlights – 26th Annual Conference of Cardiological Society of India, Delhi Chapter

Audio highlights – 26th Annual Conference of Cardiological Society of India, Delhi Chapter Dr V K Behl on STEMI Dr S S Kothari on Cardiac Hemodynamics. Joke by Dr Vijay Trehan Dr A K Omar on Newer anti platelet drugs Dr Balbir Singh on CRT Col CP Roy on Lipids therapy Dr Rakesh Yadav on …

Continue reading »

Nov 28

Kindly visit face book for CSI News

Kindly visit face book for CSI News, it will cover minute to minute happenings of 63rd CSI conference at Mumbai 8-11th December 2011 https://www.facebook.com/pages/CSI-News/313314812030443?sk=wall

Nov 28

Catheter Induced Pseudoaneurysm Of Femoral Artery-Detection And Treatment.

Dr Vivek Kumar, Dr Preetam Patil, Fortis Escorts Heart Institute and Research Center A pseudoaneurysm is a pulsatile hematoma that communicates with an artery through a disruption in the arterial wall. Femoral pseudoaneurysm is a common complication of invasive procedures. It occurs in 0.1% to 0.2% of diagnostic angiograms and 3.5% to 5.5% of interventional …

Continue reading »

Nov 28

Electronic BP instruments underestimate the BP

Electronic blood pressure measurement using an automated manometer tends to underestimate the blood pressure when compared with manual measurement. Since hypertension has been defined using manual recordings of blood pressure, readings obtained using automated electronic manometers may underestimate the real time estimation of blood pressure making a significant difference to patient care and should be …

Continue reading »

Nov 28

TCT 2011: KEY TRIALS: The Transcatheter Cardiovascular Therapeutics

1. STACCATO: A study comparing the Transapical approach for transcatheter aortic-valve implantation (TAVI) against conventional aortic-valve replacement surgery was stopped due to an increase in adverse events in the TAVI arm 2. PARTNER A (QoL and Efficacy): A quality-of-life assessment in a trial comparing the transfemoral vs Transapical route in high-risk, surgery-eligible patients showed substantial …

Continue reading »

Nov 28

AHA 2011: Key Cardiology Trials of 2011

AIM-HIGH: Stopped early at three years due to unexplained increase in ischemic stroke in the niacin group vs placebo; experts now say trial should not have stopped. SATURN: High-dose statin therapy resulted in significant regression of coronary atherosclerosis ATLAS: Rivaroxaban 2.5 mg has shown promising results ELEVATE: Clopidogrel 225 mg for patients with one loss-of-function …

Continue reading »

Nov 28

The European Society of Cardiology: ESC 2011 Key Trials

ARISTOTLE: New oral factor Xa apixaban is superior to warfarin in preventing stroke or systolic embolism and is associated with less bleeding and lower mortality than warfarin ASCOT-LLA: Treatment with 10 mg of atorvastatin reduces all-cause mortality compared with placebo, mainly through a reduction in non cardiovascular deaths dal-VESSEL: Treatment with dalcetrapib 600 mg daily …

Continue reading »

Nov 28

Predictors of bleeding with anti platelet drugs

The known risk factors for bleeding include age greater than 75 years, female sex, baseline anemia, and chronic kidney disease. In the TRITON-TIMI additional major predictors of serious bleeding were use of a glycoprotein IIb/IIIa inhibitor, duration of intervention, assignment to prasugrel, ST-elevation myocardial infarction, and hypercholesterolemia (Circulation 2011; 123:2681..)  

Nov 28

Enoxaparin versus heparin in acute STEMI

In the ATOLL trial, which randomly assigned over 900 STEMI patients to enoxaparin or UFH before PPCI, there was a non-significant reduction in the rate of the primary outcome of death. (Lancet 2011; 378:693)

Nov 28

Facts and Figures in Cardiology

The incidence of heart attack is 12.9/1000 in men 30 to 34 years old and 5.2/1000 in women 35 to 44 years old.